Skip to Content
Interactive Textbook on Clinical Symptom Research Logo


Home Button

Clinical Trials in TMD Sections
Author Bio
Introduction
The Biopsychosocial Model
Designing Multicenter RCTs
Players in an RCT
Randomization
Currently selected section: Trial Design Quality
TMD Case Definition
Endpoints and Outcome Measures
Blinding & Masking
Study Sample Size
Number and Nature of Interventions
Study Length and Follow up
Intent-to-treat Analyses and Sample Size
Compliance
Multicenter RCTs
Implementing RCTs: Practical Issues
Analysis of TMD Trials
Conclusions
Acknowledgments
Appendix A
Appendix B

 

Chapter 22: Clinical Trials in Temporomandibular: Trial Design Quality
        

Although there is ample research to show that randomized control trials are the strongest type of research design to measure the efficacy of a treatment modality, what about the quality of the randomized control trial itself? Do higher quality studies yield different results than lower quality studies? What study features seem to be most important?

Multiple research studies have recently begun to address these pertinent questions, and, although the answers are far from certain, specific features of RCTs that investigate treatments in humans have been shown to be especially valuable.

Common rating schemas have been established by both the Cochrane Collaboration www.cochrane.org and by CONSORT (consolidated standards of reporting trials). Altman and others (Altman et al., 2001), for example, developed a checklist of 22 items to include in published reports of RCTs, and this is listed in Table 6.1. The National Library of Medicine, the Journal of the American Medical Association, the International Committee of Medical Journal Editors, and over 20 other biomedical journals have all endorsed the CONSORT criteria.

Out of these 22 items, not surprisingly, larger trials (group sizes greater than 1000) have been shown to yield results that are less variable, more conservative, and closer to the overall mean effect of all trials averaged together than smaller trials (Kjaergard et al., 2001a; Juni et al., 2001c). Very small trials (less than ~30 subjects per group) have been shown to do the opposite; these trials inflate estimates of treatment effectiveness, yield widely varying results, and are generally farther from the average of all treatment studies (Kjaergard et al., 2001b).

As a general rule, RCTs that adhere to strict criteria are more likely to yield studies that are closer to the average of all trials conducted, whether they are large or small in size (Juni et al., 2001a), although a recent paper was unable to replicate this finding (Balk et al., 2002).

An excellent series of articles by Turk and colleagues discuss many usually neglected factors that influence outcomes in chronic pain treatment studies (Turk and Rudy, 1990; Turk and Rudy, 1991; Turk et al., 1993). The issues raised include non-compliance with study tasks and lack of agreement on outcome evaluation criteria, which are especially critical when attempting RCT's involving clinical conditions defined more by subjective symptom states than by objective pathophysiologic markers.




Page 25 of 81
      Previous Section